The groundbreaking success of Viagra undeniably transformed the pharmaceutical landscape, but investing in companies heavily reliant on generic versions presents a complex picture. Although early returns were significant, the cessation of patents and the rise of less expensive alternatives have weakened the customer base. Consequently, a thorough a